TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s ...

Valuation Methodology - The valuation model assumes free cash flow will grow at a constant annual rate over the next eight years, with each year's projected cash flow discounted back to present value using a fixed discount rate derived via the Capital Asset Pricing Model (CAPM) [1] - A terminal value is calculated by projecting free cash flow into the ninth year, assuming it continues to grow at the same rate, and applying a perpetual growth rate using the Gordon Growth Model, which is also discounted back to present value [1] - Key assumptions include constant growth and discount rates over time, the discount rate exceeding the perpetual growth rate to ensure a finite terminal value, and accurate free cash flow projections reflecting future performance without unexpected changes [1] Investment Strategy - The analyst advocates for a disciplined risk management approach through a barbell strategy, allocating 90% to safe assets and 10% to high-growth opportunities to balance security with potential upside [1] Disclosure and Disclaimer - The article is intended to provide informational content and should not be viewed as an exhaustive analysis or personalized investment advice [3] - The predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty [3] - Readers are advised to independently verify the information and conduct their own research before making any investment decisions [3]

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings Evaluated against current standards of care, single doses of REGN7508 and REGN9933 administered 12 to 24 hours after total knee replacement demonstrated robust antithrombotic effects Phase 3 program to be initiated in 2025 TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmac ...

Regeneron Pharmaceuticals (REGN) announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following retinal vein occlusion (RVO). The intended patient population includes those with central, branch and hemiretinal vein occlusions.Eylea is Regeneron’s blockbuster eye disease drug, which is already approved for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and RVO.The FDA has ...

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived ...

EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the primary endpoint was met ...

TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company's leadership in adopting responsible practices that drive business resilience and improve our world. The DJSI World Index is a leading benchmark for corporate responsi ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Regeneron Underperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchEylea Sales Decline Hampers REGN's Ophthalmology UnitEylea is an ...

LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Regeneron investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you ca ...

BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) investors concerning the Company's possible violations of federal securities laws. On April 10, 2024, the US Department of Justice ("DOJ") announced the United States had filed a complaint against Regeneron under the False Claims Act. That announcement stated the complaint "alleges that Regeneron fraudulently in ...